Actelion reports earnings

Actelion (SWX:ATLN) reported second quarter basic EPS of CHF0.52, up 33% from EPS of CHF0.39 for the same period last year. Second quarter revenues were up 63% to CHF113.9 million ($89.9 million) from CHF69.9 million ($55.2 million) in the second quarter of 2003.

Revenues were driven by continued growth of Tracleer bosentan to treat pulmonary arterial hypertension (PAH). The drug posted CHF108 million ($85 million) in second quarter sales, up 61% from CHF67.2 million ($53 million) for the same period last year. Second quarter sales of Zavesca N-butyldeoxynojirimycin glucosyltransferase to treat Type I Gaucher's disease were CHF1.5 million ($1.2 million). ...